NIOSHTIC-2 Publications Search
Urinary Cancer-Related Protein EDC1 as Immunodiagnostic Marker in Breast Cancer.
Chawla-RK; Miller-FW; Lawson-DH; Richmond-A; Nixon-DW; Rudman-D
NIOSH 1982 Apr:600-621
The usefulness of EDC1 proteinuria as an immunodiagnostic agent was explored in a population of patients with adenocarcinoma of the breast. The level of this protein was determined in the patients, in age and sex matched healthy individuals, in noncancer hospitalized patients, and in preoperative patients presenting initially with a localized breast mass. The work thus far completed indicates no significant accumulation of EDC1 in the plasma of normal or metastatic breast cancer patients. However, EDC1 was a minor component of normal urine and its excretion in metastatic breast cancer was significantly elevated. Heavy excretion of IR- EDC1 was also observed in the noncancer group of patients with renal insufficiency, rheumatoid arthritis, and certain infectious diseases. When the urine was appropriately pretreated to remove the interfering high molecular weight material, this source of false positives was eliminated. Of the 25 preoperative patients with malignant tumors, 12 excreted more than 30 milligrams EDC1/gram creatinine. Following surgical removal of the tumor the urinary output of EDC1 dropped significantly. The researchers suggest that EDC1 proteinuria is a reliable tool to monitor a patient's response to prescribed therapy. Whether the immunodiagnostic agent can be used to predict a recurrence of the disease is not known at present.
Protein-chemistry; Protein-synthesis; Urinalysis; Diagnostic-techniques; Breast-cancer; Blood-analysis; Humans;
Proceedings of the Second NCI/EPA/NIOSH Collaborative Workshop: Progress on Joint Environmental and Occupational Cancer Studies, September 9-11, 1981, Rockville, Maryland
Page last reviewed: May 5, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division